作者
Isabel Leroux-Roels, Matthew G Davis, Katie Steenackers, Brandon Essink, Corinne Vandermeulen, Charles Fogarty, Charles P Andrews, Edward Kerwin, Marie-Pierre David, Laurence Fissette, Carline Vanden Abeele, Delphine Collete, Magali de Heusch, Bruno Salaun, Nathalie De Schrevel, Juliane Koch, Céline Verheust, Nancy Dezutter, Frank Struyf, Narcisa Mesaros, Jelena Tica, Veronica Hulstrøm
发表日期
2023/3/15
期刊
The Journal of Infectious Diseases
卷号
227
期号
6
页码范围
761-772
出版商
Oxford University Press
简介
Background
The aim of this study was to investigate safety and immunogenicity of vaccine formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion conformation of RSV fusion protein (RSVPreF3).
Methods
This phase 1/2, randomized controlled, observer-blind study enrolled 48 young adults (YAs; aged 18–40 years) and 1005 older adults (OAs; aged 60–80 years) between January and August 2019. Participants were randomized into equally sized groups to receive 2 doses of unadjuvanted (YAs and OAs) or AS01-adjuvanted (OAs) vaccine or placebo 2 months apart. Vaccine safety and immunogenicity were assessed until 1 month (YAs) or 12 months (OAs) after second vaccination.
Results
The RSVPreF3 vaccines boosted humoral (RSVPreF3-specific immunoglobulin G [IgG] and RSV-A neutralizing antibody) responses …
学术搜索中的文章
I Leroux-Roels, MG Davis, K Steenackers, B Essink… - The Journal of Infectious Diseases, 2023